Adarx Closes A $602.5M IPO And Private Placement For SiRNA Runway

With approximately $602.5 million in combined gross proceeds now closed, ADARx Pharmaceuticals enters the public markets with a capital position that will shape contract manufacturing demand and API sourcing decisions across the siRNA supply chain. The San Diego-based company completed its Nasdaq IPO on October 1, 2026, following full exercise of the underwriters' overallotment option, a signal of institutional confidence in late-stage RNA therapeutics programs.

The offering comprised 30,187,500 shares priced at $17.00 per share, generating approximately $513.2 million in gross IPO proceeds before underwriting discounts and commissions. A concurrent private placement to AbbVie, 5,255,542 shares at the same $17.00 price, contributed an additional $89.3 million and formalises a collaboration and license option agreement spanning siRNA development in neuroscience, immunology, and oncology.

For manufacturing and supply-chain leads, the AbbVie relationship carries operational weight beyond the capital infusion. A multi-indication siRNA collaboration of this scope typically triggers parallel CMC workstreams, including process characterisation, analytical method transfer, and scaled synthesis of chemically modified oligonucleotides, each carrying its own ICH Q10 quality system obligations as programs advance toward IND-enabling studies and eventual 21 CFR Part 211 commercial readiness.

ADARx's pipeline spans complement-mediated, cardiovascular, thrombosis, CNS, and metabolic disease indications, with wholly-owned programs running alongside the AbbVie collaboration. The breadth of therapeutic areas suggests a diversified manufacturing demand profile, with different delivery and formulation requirements across programs that CDMOs and API suppliers will need to accommodate as clinical timelines firm up.

Registration statements became effective September 24, 2026, with J.P. Morgan, Morgan Stanley, TD Cowen, and UBS Investment Bank serving as lead book-running managers; LifeSci Capital acted as book-running manager.

The measurable near-term checkpoint is how ADARx allocates capital across its pipeline prioritisation decisions, which will determine which programs reach process validation-stage manufacturing engagements first.

Source: GlobeNewswire via ADARx Pharmaceuticals press release, October 1, 2026.